CF Foundation Awards Over $2 Million for Cystic Fibrosis Treatment Development
source: pixabay.com

CF Foundation Awards Over $2 Million for Cystic Fibrosis Treatment Development

The Cystic Fibrosis Foundation is dedicated to finding a cure for the rare, genetic disorder. They fund more CF research than any other organization, and their latest effort is a…

Continue Reading CF Foundation Awards Over $2 Million for Cystic Fibrosis Treatment Development
NTM Lung Disease Treatment ARIKAYCE Given European Marketing Authorization
kalhh / Pixabay

NTM Lung Disease Treatment ARIKAYCE Given European Marketing Authorization

Early on October 28, 2020, Insmed Inc. ("Insmed") announced that it received Marketing Authorization from the European Commission for ARIKAYCE. This therapy is designed for adult patients with nontuberculous mycobacterial…

Continue Reading NTM Lung Disease Treatment ARIKAYCE Given European Marketing Authorization

Interim Results from Phase 2a Trial for Nontuberculous Mycobacterial Lung Disease Bring Hope

Nontuberculous mycobacterial (NTM) lung infection occurs when someone inhales nontuberculous mycobacteria from the environment. There are various types of this bacteria, giving NTM different forms. But in all types of NTM,…

Continue Reading Interim Results from Phase 2a Trial for Nontuberculous Mycobacterial Lung Disease Bring Hope
Arikayce® Granted Accelerated Approval by the FDA for the Treatment of MAC Lung Disease
jniittymaa0 / Pixabay

Arikayce® Granted Accelerated Approval by the FDA for the Treatment of MAC Lung Disease

A new drug designed to treat MAC lung disease as part of a combination antibacterial drug regimen in adults with limited treatment options has been granted Accelerated Approval by the…

Continue Reading Arikayce® Granted Accelerated Approval by the FDA for the Treatment of MAC Lung Disease